Last reviewed · How we verify

NCT03932851

Clinical Study on the Effect of IVF-ET on Mother-to-child Transmission of Hepatitis B Virus

Status unknown Last updated 1 May 2019
What this trial tests

trial testing IVF-ET in Pregnancy in 400 participants. Status unknown.

Timeline
1 August 2018
Primary endpoint
1 May 2019
1 May 2019

Quick facts

Lead sponsorBeijing Ditan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 August 2018
Primary completion1 May 2019
Estimated completion1 May 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Ditan Hospital

Who can join

Adults 18 to 35, female only, with Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is intended to retrospectively collect HBV-infected pregnant women and non-HBV-infected pregnant women who have been born in IVF in the investigators' hospital, collect pregnant women's data during pregnancy, newborn birth data, and hepatitis B virus in July after birth of newborns born to HBV-infected pregnant women. Infection, explore the impact of HBV infection on IVF outcomes and whether IVF operations increase the risk of mother-to-child transmission of HBV.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pregnancy

Currently open trials in the same condition.

Other Beijing Ditan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing